![logo](/logos/EOLS.webp)
Evolus, Inc.
NASDAQ:EOLS
14.71 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Evolus, Inc. |
Symbool | EOLS |
Munteenheid | USD |
Prijs | 14.71 |
Beurswaarde | 928,120,095 |
Dividendpercentage | 0% |
52-weken bereik | 7.44 - 16.29 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. David Moatazedi |
Website | https://www.evolus.com |
An error occurred while fetching data.
Over Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)